developmenteua

6 results found.

Top Stocks matching your search for "development eua"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
EDSA

Edesa Biotech Inc

-24.09%

$1.37 - $1.04

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 11, 2023

$EDSA It certainly is an interesting development.

Jan, 6, 2023

$EDSA strong accumulation in 2-2.50 range; indep... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
OCGN

Ocugen Inc

-23.15%

$1.24 - $0.95

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 17, 2023

Any positive development is just going to solidify... See more

Feb, 7, 2023

They worked with leading experts in the field to d... See more

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
ARCT

Arcturus Therapeutics Holdings Inc

-24.86%

$19.59 - $14.72

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Nov, 2, 2022

$ARCT This is very positive development for ARCT.

EDSA

Edesa Biotech Inc

-24.09%

$1.37 - $1.04

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 11, 2023

$EDSA It certainly is an interesting development.

Jan, 6, 2023

$EDSA strong accumulation in 2-2.50 range; independent of economic/rate developments and string P2 results all point to a significant upside in the next month.

Nov, 13, 2022

A positive development in terms of upcoming P2 data.

OCGN

Ocugen Inc

-23.15%

$1.24 - $0.95

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 17, 2023

Any positive development is just going to solidify the uptrend that is taking place on the technicals $JNJ $ABBV $OCGN $APLS

Feb, 7, 2023

They worked with leading experts in the field to develop innovative therapies for a range of ocular diseases, and their products were met with great excitement and anticipation.

Jan, 12, 2023

$OCGN “We are eager to get started on the final phase of NeoCart® development and pleased at the outcome of our discussions with the FDA”

Dec, 27, 2022

The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics,” said Krishna Ella, executive chairman of Bharat Biotech.

Oct, 3, 2022

Revenue means security for future development and ocgn’s whole pipeline will gain value because of it.

ARCT

Arcturus Therapeutics Holdings Inc

-24.86%

$19.59 - $14.72

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Nov, 2, 2022

$ARCT This is very positive development for ARCT.